Trialling personalised cancer medicine

The challenge Non-small cell lung cancer is the most common type of lung cancer. However, as it is caused by a range of specific mutations which vary between patients, individuals won’t all respond in the same way to the same treatment. This presents a clear opportunity for the use of precision medicine – however, setting up numerous individual clinical trials can be a barrier as it is inefficient in terms of patient care and investment … Continue reading “Trialling personalised cancer medicine”